PPARGC1A and neoplasm: These experimental results show that pGC-1α agonists combined with PD-1/PD-L1 antibodies enhance the tumour-killing ability of CD8+ TILs and support the great potential of PPAR as a fatty acid metabolism target, as mentioned above.